Galapagos | Driftsresultat



Operating Profit Lave om Dato
argenx SE USD 103.04M 86.87M 2024-12
AstraZeneca USD 2.04B 731M 2024-12
Biogen USD 441.4M 24.4M 2024-12
Genmab DKK 2.19B 89M 2024-12
Gilead Sciences USD 2.45B 1.56B 2024-12
GlaxoSmithKline GBP 696M 507M 2024-12
GRIFOLS EUR 371.86M 54.83M 2024-12
Hikma Pharmaceutical USD 327M 208M 2024-06
Incyte USD 301.51M 155.43M 2024-12
Merck EUR 1.1B 305M 2024-09
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Roche Holding CHF 4.39B 1.04B 2024-12
Sanofi EUR 4.09B 1.81B 2024-09
UCB EUR 163M 39M 2024-06
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Galapagos Driftsresultat - Aktuelle værdier, historiske data, prognoser, statistik, diagrammer og økonomisk kalender - Mar 2025.